Skip to main
SOPH

SOPH Stock Forecast & Price Target

SOPH Analyst Ratings

Based on 3 analyst ratings
Strong Buy
Strong Buy 100%
Buy 0%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

Sophia Genetics is favored because its cloud-based, pay-per-use SaaS model delivers recurring, high-margin revenue while avoiding reimbursement risk, with 2025 revenue of $77.3M growing 19% YoY and adjusted gross margin reaching 74.2%. Its moat is reinforced by a compounding network of roughly 1,000 institutions across 75 countries and more than 2.5M genomic profiles, which supports strong retention, 117% net dollar retention in 1Q26, and rising ASPs. The outlook is further strengthened by deepening U.S. adoption and biopharma traction, including MSK and MD Anderson collaborations, two large U.S. health-system commitments totaling about 60K analyses annually, and 2026 revenue guidance of $92M to $94M.

Bears say

Sophia Genetics is viewed negatively because its core SOPHiA DDM platform appears unable to convert volume growth into strong revenue growth, with 2024 revenue up just 4% despite 11% volume growth, implying a 6-7% decline in revenue per analysis amid biopharma headwinds. The bear case assumes BioPharma DDM remains only about 5% of revenue from 2026 to 2033, limiting total revenue to $441M at peak and leaving adjusted gross margin flat near 70% with little operating leverage. It also remains unprofitable, faces commercial, competitive, cybersecurity, legal, and dilution risks, and the Guardant Health patent dispute adds further uncertainty to its ability to scale efficiently.

SOPH has been analyzed by 3 analysts, with a consensus rating of Strong Buy. 100% of analysts recommend a Strong Buy, 0% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Sophia Genetics SA and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Sophia Genetics SA (SOPH) Forecast

Analysts have given SOPH a Strong Buy based on their latest research and market trends.

According to 3 analysts, SOPH has a Strong Buy consensus rating as of Oct 8, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $10, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $10, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Sophia Genetics SA (SOPH)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.